The N-linked oligosaccharide at FcγRIIIa Asn-45: An inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation

Glycobiology

Volumn 19, Issue 2, 2009, Pages 126-134

  Shibata Koyama, Mami ^a   Iida, Shigeru ^a   Okazaki, Akira ^a   Mori, Katsuhiro ^a   Kitajima Miyama, Kazuko ^a   Saitou, Seiji ^a   Kakita, Shingo ^a   Kanda, Yutaka ^b   Shitara, Kenya ^b   Kato, Koichi ^b,c   Satoh, Mitsuo ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c OKAZAKI INSTITUTE FOR INTEGRATIVE BIOSCIENCE   (Japan)

Author keywords

Fc RIIIa Asn 45; Fc RIIIa binding affinity; IgG1 lacking core fucosylation; N linked Fc oligosaccharides; N linked Fc RIIIa oligosaccharides

Indexed keywords

ASPARAGINE; ASPARAGINE LINKED OLIGOSACCHARIDE; CELL RECEPTOR; HUMAN LEUKOCYTE RECEPTOR IIIA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; FUCOSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; RECEPTOR BINDING; STRUCTURE ANALYSIS; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIGENS, CD20; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; FUCOSE; HUMANS; IMMUNOGLOBULIN G; MODELS, BIOLOGICAL; OLIGOSACCHARIDES; RECEPTORS, IGG; SURFACE PLASMON RESONANCE;

EID: 58149343570     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwn110     Document Type: Article

References (35)

1. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. 2003. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:455-459.
2. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Waitier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754-758.
3. Clark MR. 1997. IgG effector mechanisms. Chem Immunol. 65:88-110.
4. Dall'Ozzo S, Tartas S, Paintaud G, Carton G, Colonbat P, Bardos P, Watier H, Thibaut G. 2004. Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64:4664-4669.
5. Dresher B, Witte T, Schimidt RE. 2003. Glycosylation of FcγRIII in N163 as mechanism of regulating receptor affinity. Immunol. 110:335-340.
6. Ferrara C, Stuart F, Sondermnann P, Brunker P, Umana P. 2006. The carbohydrate at FcγRIIIa Asn-162: An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem. 281:5032-5036.
7. Galon J, Robertson MW, Galinha A, Mazieres N, Spagnoli R, Fridman WF, Sautes C. 1997. Affinity of the interaction between Fc gamma receptor type III (FcγRIIIa) and monomeric human IgG subclasses. Role of FcγRIII glycosylation. Eur J Immunol. 27:1928-1932.
8. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti M, Gibelli N, et al. 2004. Pilot study of the mechanism of action of preoperative tratuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 10:5650-5655.
9. Harris LJ, Skaletsky E, Mcpherson A. 1998. Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 275:861-872.
10. Huber R, Deisenhofer J, Colman PM. 1976. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature. 264:415-420.
11. Iida S, Misaka H, Inoue M, Sibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M. 2006. Non-fucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum IgG on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin Cancer Res. 12(9):2879-2887.
12. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. 2006. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology. 17:104-118.
13. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park, YH, Do YR, Shin HJ, Kim MK, Hyun MS, et al. 2006. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 108:2720-2725.
14. Krapp, S, Mimura Y, Jefferis R, Huber R, Sondermann PJ. 2003. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. Mol. Biol. 325:979-989.
15. Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF, et al. 2004. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 19:511-519.
16. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K. 2007. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 368(3):767-779.
17. Miescher S, Spycher MO, Amstutz H, De Haas M, Kleijer M, Kalus UJ, Radtke H, Hubsch A, Andresen I, Martin RM, et al. 2004. A single recombinant anti-RhD IgG prevents RhD immunization: Association of RhD-positive red blood cell clearance rate with polymorphisms in the FcγRIIA and FcγIIIA genes. Blood. 103:4028-4035.
18. Morgan A, Jones ND, Nesbitt AM, Chaplin L, Bodmer MW, Emtage JS. 1995. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for Ci1q, FcRI and FcRIII binding. Immunology. 86:319-324.
19. Nakanuma K, Tanaka Y, Fujino I, Hirayama N, Shitara K, Hanai N. 2000. Dissection and optimization of immune effector function of humanized anti-ganglioside GM2 monoclonal antibody. Mol Immunol. 37:1035-4106.
20. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K. 2004. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin Cancer Res. 10:6248-6255.
21. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. 2005. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 11:2327-2336.
22. Niwa R, Shoji-Hosaka E, Sakurada M, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. 2004. Defucosylated chimeric anti-CC chemokine receptor 4IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64:2127-2133.
23. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumato K, Kumagai I, Shitara K. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol. 336:1239-1249.
24. Papac D, Wong A, Jones AJ. 1996. Analysis of acidic oligosaccharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem. 68:3215-3223.
25. Radaev S, Motyka S, Fridman W, Sautes-Fridman C, Sun PD. 2001. The structure of a human type III Fcγ receptor in complex with Fc. J Biol Chem. 276:16469-16477.
26. Ravetch JV, Perussia B. 1989. Alternative membrane forms of FcγRIII (CD16) on human natural killer cells and neutrophils. J Exp Med. 170:481-497.
27. Satoh M, Iida S, Shitara K. 2006. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Exp Opin Biol Ther. 6:1161-1173.
28. Shields RL, Lai J, Keck R, O'connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem. 277:26733-26740.
29. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 278:3466-3673.
30. Sondermann P, Huber R, Oosthyzen V, Lacob U. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406:267-273.
31. Suzuki A, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, et al. 2007. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res. 13:1875-1882.
32. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, et al. 2005. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol. 23:474-481.
33. Urlaub G, Chasin LA. 1980. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci USA 77:4216-4220.
34. Weng WK, Levy R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 21:3940-3947.
35. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 87:614-622.